Centro Hospitalar Do Baixo Vouga E.P.E. (CHBV E.P.E.)

The trial at Centro Hospitalar Do Baixo Vouga E.P.E. explores a new selatogrel therapy that patients can self‑administer when they experience symptoms of acute myocardial infarction. The goal is to determine whether early, patient‑driven treatment reduces the likelihood of a recurrent heart attack.

• Patient‑initiated emergency medication
• Evaluation of rapid symptom response
• Impact on recurrent heart attack rates

Findings could shape future emergency protocols for individuals at high cardiovascular risk.

Researchers at Centro Hospitalar Do Baixo Vouga E.P.E. are testing olpasiran to see if lowering lipoprotein(a) can decrease the incidence of coronary heart disease death, myocardial infarction, or urgent revascularisation in patients with atherosclerotic cardiovascular disease. The study compares the drug to placebo to assess long‑term cardiovascular risk reduction.

• Lp(a) lowering strategy
• Prevention of major cardiac events
• Placebo‑controlled efficacy assessment

Successful results may provide a novel preventative option for people with elevated Lp(a) levels.